Journal of Pain Management and Therapy

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +1 (202) 780-3397

Opinion Article - Journal of Pain Management and Therapy (2024) Volume 8, Issue 2

Understanding anxiolytics comprehensive overview

Sathwik Avasarala*

Department of Medicine, University of North Carolina School of Medicine, United States

*Corresponding Author:
Sathwik Avasarala
Department of Medicine, University of North Carolina School of Medicine, United States
University of North Carolina School of Medicine
United States

Received:20-Feb-2024, Manuscript No. AAPMT-24-130198; Editor assigned: 23-Feb-2024, PreQC No. AAPMT-24-130198(PQ); Reviewed:08-Mar-2024, QC No. AAPMT-24-130198; Revised:13-Mar-2024, Manuscript No. AAPMT-24-130198(R); Published:20-Mar-2024, DOI:10.35841/ aapmt-8.2.197

Citation: Avasarala S. Understanding anxiolytics comprehensive overview. J Pain Manage Ther. 2024;8(2):197

Visit for more related articles at Journal of Pain Management and Therapy


Anxiety disorders are among the most prevalent mental health conditions globally, affecting millions of individuals across all age groups. Characterized by persistent, excessive worry and fear, these disorders can significantly impair daily functioning and quality of life. Fortunately, an array of pharmacological interventions, known as anxiolytics, is available to alleviate symptoms and promote well-being. This article aims to provide a comprehensive overview of anxiolytics, including their mechanisms of action, types, effectiveness, and potential side effects[1,2].

Before delving into anxiolytics, it's crucial to understand the nature of anxiety itself. Anxiety is a natural response to stress or perceived threats, often serving as a protective mechanism. However, when anxiety becomes chronic or disproportionate to the situation, it can lead to debilitating symptoms and impairment. Anxiety disorders encompass various conditions, including Generalized Anxiety Disorder (GAD), panic disorder, social anxiety disorder, and specific phobias[3].

Anxiolytics work by targeting neurotransmitter systems in the brain involved in regulating emotions and stress responses. The primary neurotransmitters implicated in anxiety disorders are gamma-aminobutyric acid, serotonin, and norepinephrine. GABA is an inhibitory neurotransmitter that helps reduce neuronal excitability, promoting relaxation and dampening anxiety. Serotonin and norepinephrine play crucial roles in mood regulation, with imbalances in these neurotransmitters linked to anxiety symptoms[4].

Benzodiazepines these drugs enhance the activity of GABA receptors, leading to sedative, anxiolytic, and muscle-relaxant effects. Examples include alprazolam (Xanax), diazepam (Valium), and lorazepam (Ativan). Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs increase serotonin levels in the brain by inhibiting its reuptake, thereby alleviating anxiety symptoms over time. Common SSRIs prescribed for anxiety include sertraline (Zoloft), fluoxetine (Prozac), and escitalopram (Lexapro)[5].

Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) such as venlafaxine (Effexor) and duloxetine (Cymbalta), inhibit the reuptake of both serotonin and norepinephrine, offering dual benefits in managing anxiety and depressive symptoms. Buspirone Unlike benzodiazepines, buspirone acts as a partial agonist at serotonin receptors and may also modulate dopamine activity. It is commonly used for generalized anxiety disorder and lacks the sedative and addictive properties of benzodiazepines[6].

The effectiveness of anxiolytics varies depending on the individual and the specific type of anxiety disorder. Benzodiazepines provide rapid relief of symptoms but are associated with tolerance, dependence, and withdrawal upon discontinuation, limiting their long-term use. SSRIs and SNRIs may take several weeks to exert their full therapeutic effects but are generally safer and have a lower risk of dependence. Buspirone, while effective for some individuals, may require several weeks of treatment to achieve noticeable improvements in symptoms. It is often preferred for long-term management due to its favourable side effect profile and lower risk of abuse[7].

Like all medications, anxiolytics can cause side effects, which vary depending on the drug and individual factors. Common side effects of benzodiazepines include drowsiness, dizziness, cognitive impairment, and potential for addiction. SSRIs and SNRIs may cause nausea, sexual dysfunction, weight changes, and sleep disturbances initially, although these often diminish over time. Buspirone’s side effects may include dizziness, headaches, and nausea, but it generally has fewer adverse effects compared to other anxiolytics[8].

Anxiolytics play a crucial role in the management of anxiety disorders, offering relief from distressing symptoms and improving overall functioning. However, their use should be carefully monitored, considering individual differences, potential side effects, and the risk of dependence. Collaborative decision-making between patients and healthcare providers is essential to determine the most appropriate treatment approach, which may include a combination of pharmacotherapy, psychotherapy, and lifestyle modifications. With proper management, individuals with anxiety disorders can experience significant improvements in their well-being and quality of life[9, 10].


  1. Cumming RG, Klineberg RJ. Psychotropics, thiazide diuretics and hip fractures in the elderly. Med J Aust. 1993;158(6):414-7.
  2. Indexed at, Google Scholar, Cross Ref

  3. Ensrud KE, Blackwell T, Mangione CM, et al. Study of Osteoporotic Fractures Research Group. Central nervous system active medications and risk for fractures in older women. Arch Intern Med. 2003;163(8):949-57.
  4. Indexed at, Google Scholar, Cross Ref

  5. Ray WA, Griffin MR, Schaffner W, et al. Psychotropic drug use and the risk of hip fracture. N Engl J Med. 1987;316(7):363-9.
  6. Indexed at, Google Scholar, Cross Ref

  7. Wang PS, Bohn RL, Glynn RJ, et al. Zolpidem use and hip fractures in older people. J Am Geriatr Soc. 2001;49(12):1685-90.
  8. Indexed at, Google Scholar, Cross Ref

  9. Cauley JA, Lui LY, Genant HK. Study of Osteoporotic Fractures Research Group. Ann Intern Med. 1999;130(1):270-7.
  10. Google Scholar

  11. Ataya K, Mercado A, Kartaginer J, et al. Bone density and reproductive hormones in patients with neuroleptic-induced hyperprolactinemia. Fertil Steril. 1988;50(6):876-81.
  12. Indexed at, Google Scholar, Cross Ref

  13. Higuchi T, Komoda T, Sugishita M, et al. Certain neuroleptics reduce bone mineralization in schizophrenic patients. Neuropsychobiology. 1987;18(4):185-8.
  14. Indexed at, Google Scholar, Cross Ref

  15. Whooley MA, Kip KE, Cauley JA, et al. Study of Osteoporotic Fractures Research Group. Depression, falls, and risk of fracture in older women. Arch Intern Med. 1999;159(5):484-90.
  16. Indexed at, Google Scholar, Cross Ref

  17. Mussolino ME, Jonas BS, Looker AC. Depression and bone mineral density in young adults: results from NHANES III. Psychosom Med. 2004;66(4):533-7.
  18. Indexed at, Google Scholar, Cross Ref

  19. Wong SY, Lau EM, Lynn H, et al. Depression and bone mineral density: is there a relationship in elderly Asian men? Results from Mr. Os (Hong Kong). Osteoporos Int. 2005;16:610-5.
  20. Indexed at, Google Scholar, Cross Ref

Get the App